Abetimus

Abetimus
Gene therapy
Clinical data
ATC code	L04AA22 (WHO) ;
Physiological data
Legal status
Pharmacokinetic data
Identifiers
CAS Number	169147-32-4 ;
ChemSpider	NA ;
Chemical and physical data
	Template:Xmark (what is this?) (verify)

Abetimus is an immunosuppressant.^[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.^[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way Abetimus is supposed to help treat Systemic Lupus Erythematosus and specifically nephritis.

References

↑ (not listed) (2003). "Abetimus: Abetimus sodium, LJP 394". BioDrugs. Adis. 17 (3): 212&ndash, 215. doi:10.2165/00063030-200317030-00009. ISSN 1173-8804. PMID 12749759.
↑ Wallace, Daniel J. (January 2001), "Clinical and pharmacological experience with LJP-394", Expert Opinion on Investigational Drugs, Informa, 10 (1), pp. 111&ndash, 117, doi:10.1517/13543784.10.1.111, ISSN 1354-3784, PMID 11116284, retrieved 2 April 2011

Template:Immunosuppressants

Template:Antineoplastic-drug-stub

[pmid12749759-1] (not listed) (2003). "Abetimus: Abetimus sodium, LJP 394". BioDrugs. Adis. 17 (3): 212&ndash, 215. doi:10.2165/00063030-200317030-00009. ISSN 1173-8804. PMID 12749759.

[2] Wallace, Daniel J. (January 2001), "Clinical and pharmacological experience with LJP-394", Expert Opinion on Investigational Drugs, Informa, 10 (1), pp. 111&ndash, 117, doi:10.1517/13543784.10.1.111, ISSN 1354-3784, PMID 11116284, retrieved 2 April 2011

[1]

[2]

Gene therapy
Clinical data
ATC code	L04AA22 (WHO)
Physiological data
Legal status
Pharmacokinetic data
Identifiers
CAS Number	169147-32-4^N
ChemSpider	NA^Y
Chemical and physical data
^{Template:XmarkY} (what is this?) (verify)